Medexus Pharmaceuticals (MDP.T), a Canadian specialty pharma company servicing both the Canadian and American markets, has built a sizeable drug portfolio with continuing growth potential.

It’s already been a good year for revenues and now analyst estimates suggest the innovative company’s combined sales could surpass $100 million USD in 2023.

Specialty drugs are used to treat complex chronic and life threatening conditions, making it a niche market with high margins and low marketing costs.

The global specialty drug market was estimated at $1.81 billion USD in 2021 and is expected to reach $3.98 billion by 2027. Ken d’Entremont, CEO and director, sits down with Chris Parry to talk about the company, its current growth potential and its treosulfan timeline.

Enjoy!